-
Something wrong with this record ?
Glycogen as an advantageous polymer carrier in cancer theranostics: Straightforward in vivo evidence
A. Gálisová, M. Jirátová, M. Rabyk, E. Sticová, M. Hájek, M. Hrubý, D. Jirák,
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2011
Free Medical Journals
from 2011
PubMed Central
from 2011
Europe PubMed Central
from 2011
Open Access Digital Library
from 2011-01-01
Open Access Digital Library
from 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2011
Springer Nature OA/Free Journals
from 2011-12-01
Springer Nature - nature.com Journals - Fully Open Access
from 2011-12-01
- MeSH
- Glycogen administration & dosage MeSH
- Rats MeSH
- Drug Delivery Systems * MeSH
- Cell Line, Tumor MeSH
- Neoplasms drug therapy MeSH
- Antineoplastic Agents administration & dosage MeSH
- Theranostic Nanomedicine * MeSH
- Animals MeSH
- Check Tag
- Rats MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
As a natural polysaccharide polymer, glycogen possesses suitable properties for use as a nanoparticle carrier in cancer theranostics. Not only it is inherently biocompatible, it can also be easily chemically modified with various moieties. Synthetic glycogen conjugates can passively accumulate in tumours due to enhanced permeability of tumour vessels and limited lymphatic drainage (the EPR effect). For this study, we developed and examined a glycogen-based carrier containing a gadolinium chelate and near-infrared fluorescent dye. Our aim was to monitor biodistribution and accumulation in tumour-bearing rats using magnetic resonance and fluorescence imaging. Our data clearly show that these conjugates possess suitable imaging and tumour-targeting properties, and are safe under both in vitro and in vivo conditions. Additional modification of glycogen polymers with poly(2-alkyl-2-oxazolines) led to a reduction in the elimination rate and lower uptake in internal organs (lower whole-body background: 45% and 27% lower MRI signals of oxazoline-based conjugates in the liver and kidneys, respectively compared to the unmodified version). Our results highlight the potential of multimodal glycogen-based nanopolymers as a carrier for drug delivery systems in tumour diagnosis and treatment.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028080
- 003
- CZ-PrNML
- 005
- 20210114152933.0
- 007
- ta
- 008
- 210105s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41598-020-67277-y $2 doi
- 035 __
- $a (PubMed)32591567
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Gálisová, Andrea $u MR Unit, Department of Radiodiagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 245 10
- $a Glycogen as an advantageous polymer carrier in cancer theranostics: Straightforward in vivo evidence / $c A. Gálisová, M. Jirátová, M. Rabyk, E. Sticová, M. Hájek, M. Hrubý, D. Jirák,
- 520 9_
- $a As a natural polysaccharide polymer, glycogen possesses suitable properties for use as a nanoparticle carrier in cancer theranostics. Not only it is inherently biocompatible, it can also be easily chemically modified with various moieties. Synthetic glycogen conjugates can passively accumulate in tumours due to enhanced permeability of tumour vessels and limited lymphatic drainage (the EPR effect). For this study, we developed and examined a glycogen-based carrier containing a gadolinium chelate and near-infrared fluorescent dye. Our aim was to monitor biodistribution and accumulation in tumour-bearing rats using magnetic resonance and fluorescence imaging. Our data clearly show that these conjugates possess suitable imaging and tumour-targeting properties, and are safe under both in vitro and in vivo conditions. Additional modification of glycogen polymers with poly(2-alkyl-2-oxazolines) led to a reduction in the elimination rate and lower uptake in internal organs (lower whole-body background: 45% and 27% lower MRI signals of oxazoline-based conjugates in the liver and kidneys, respectively compared to the unmodified version). Our results highlight the potential of multimodal glycogen-based nanopolymers as a carrier for drug delivery systems in tumour diagnosis and treatment.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a protinádorové látky $x aplikace a dávkování $7 D000970
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 12
- $a lékové transportní systémy $7 D016503
- 650 _2
- $a glykogen $x aplikace a dávkování $7 D006003
- 650 _2
- $a nádory $x farmakoterapie $7 D009369
- 650 _2
- $a krysa rodu Rattus $7 D051381
- 650 12
- $a teranostická nanomedicína $7 D000068936
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Jirátová, Markéta $u MR Unit, Department of Radiodiagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Department of Physiology, Faculty of Science, Charles University, Prague, Czech Republic.
- 700 1_
- $a Rabyk, Mariia $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
- 700 1_
- $a Sticová, Eva $u Department of Clinical and Transplant Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. Department of Pathology, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Hájek, Milan $u MR Unit, Department of Radiodiagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
- 700 1_
- $a Hrubý, Martin $u Institute of Macromolecular Chemistry, Academy of Sciences of the Czech Republic, Prague, Czech Republic.
- 700 1_
- $a Jirák, Daniel $u MR Unit, Department of Radiodiagnostic and Interventional Radiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic. daniel.jirak@ikem.cz. Institute of Biophysics and Informatics, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic. daniel.jirak@ikem.cz. Department of Science and Research, Faculty of Health Studies, Technical University of Liberec, Liberec, Czech Republic. daniel.jirak@ikem.cz.
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 10, č. 1 (2020), s. 10411
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32591567 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114152931 $b ABA008
- 999 __
- $a ok $b bmc $g 1608415 $s 1119260
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 10 $c 1 $d 10411 $e 20200626 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- LZP __
- $a Pubmed-20210105
